Rising Incidence Of Fetal Chromosomal Abnormalities Fuels Growth In The Carrier Screening Market: A Key Factor Shaping the Future of the Carrier Screening Market in 2025

Which drivers are expected to have the greatest impact on the over the carrier screening market's growth?
The carrier screening market is predicted to grow due to a rise in fetal chromosomal abnormalities and genetic disorders. Fetal chromosomal abnormalities are defined as an abnormal number or quantity of DNA within a fetus's chromosome. Chromosomal abnormality prenatal testing aims to accurately determine the likelihood of a patient carrying a fetus that has a chromosomal disorder. For example, estimates by the World Health Organization in February 2022 suggest that each year, 240 000 newborns die within the first 28 days of life due to birth defects. Birth defects also account for the death of an extra 170,000 children aged between 1 month and 5 years. Furthermore, a March 2022 article from the Government of the United Nations estimated that Down syndrome impacts 1 in 1,000 to 1 in 1,100 live births across the globe. Annually, this chromosome disorder affects between 3,000 and 5,000 newborns. Consequently, an uptick in fetal chromosomal abnormalities and genetic disorders fuelling the expansion of the carrier screening market.

Get Your Carrier Screening Market Report Here:
https://www.thebusinessresearchcompany.com/report/carrier-screening-global-market-report

What is the future CAGR of the carrier screening market, and how will it impact industry expansion?
The market for carrier screening has expanded at a swift pace in recent times. The market, valued at $2.72 billion in 2024, is predicted to reach $3.17 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.4%. The significant growth during the historic period is due to factors such as increased awareness of genetic disorders, a surge in maternal age, enhanced understanding of family planning and pregnancy, efforts to prevent genetic diseases, public health initiatives, and an intensified focus on inherited conditions.

Anticipations are high for a rapid expansion in the carrier screening market in the upcoming years. By 2029, it is projected to attain a market value of $5.76 billion, growing at a compound annual growth rate of 16.2%. This significant growth during the forecasted period is predicted to result from various factors like advancements in precision medicine, the introduction of expanded panel offerings, consumer genomics, and direct-to-consumer testing. Moreover, a focus on rare and ultra-rare diseases, backing from government and insurance agencies, and integration of pharmacogenomics all contribute to this advancement. The forecasted period is also expected to see key trends such as progress in genetic technologies, its incorporation with prenatal testing, and the boon in personalized medicine. Additional factors predicted to influence growth include counseling and education services, together with ethical and legal considerations.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7952&type=smp

What are the most significant trends transforming the carrier screening market today?
Significant firms in the carrier screening market are placing their attention on product enhancements, such as the family of screening tests, in order to maintain their competitive standing. Screening tests refer to medical evaluations or tests executed on people who display no signs of a specific illness or condition. For instance, in June 2023, the Finland-based company, Blueprint Genetics, who are experts in genetic examinations and diagnostics, launched their innovative product - the Screening Tests family. The product is tailored with particular intentions, including pregnancy, family planning, and detailed health analyses for asymptomatic individuals. The aim is to detect any elevated risks, hence equipping individuals with the ability to make educated decisions about family planning and general health. Blueprint Genetics is focused on offering applicable information that prompts informed choices based on existing alternatives, underlining a pledge to assist individuals in deciding about their future health.

Which key market segments comprise the carrier screening market and drive its revenue growth?
The carrier screening market size has grown rapidly in recent years. It will grow from $2.72 billion in 2024 to $3.17 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth in the historic period can be attributed to increasing genetic disorders awareness, rising maternal age, family planning and pregnancy awareness, prevention of genetic diseases, public health initiatives, increased focus on inherited conditions.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7952

What regions are at the forefront of carrier screening market expansion?
North America was the largest region in the carrier screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the carrier screening market report during the forecast period. The regions covered in the carrier screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the carrier screening market?
Major companies operating in the carrier screening market are Invitae Corporation, BGI Genomics Co. Ltd., Centogene NV, Eurofins Scientific SE, Fulgent Genetics Inc., Genealogy by Genetics Ltd., Illumina Inc., Laboratory Corporation of America Holdings, Luminex Corporation, MedGenome Inc., Myriad Genetics Inc., Natera Inc., OPKO Health Inc., Otogenetics Corporation, Quest Diagnostics Inc., Sema4 Holdings Corporation, Thermo Fisher Scientific Inc., 23andMe Holding Co., REALM IDx Inc., Associated Regional and University Pathologists Inc., Genedx LLC, Genomic Health Inc., GenPath Consultants And Technologies Private Limited, Good Start Genetics Inc., NIPD Genetics Co. Pvt. Ltd., OraSure Technologies Inc., Pathway Genomics Corp., PerkinElmer Inc., PreventionGenetics LLC, Progenity Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=7952&type=smp

What Is Covered In The Carrier Screening Global Market Report?

• Market Size Forecast: Examine the carrier screening market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the carrier screening market for a structured understanding.
• Key Players Overview: Analyze major players in the carrier screening market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the carrier screening market.
• Segment Contributions: Evaluate how different segments drive overall growth in the carrier screening market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the carrier screening market.
• Industry Challenges: Identify potential risks and obstacles affecting the carrier screening market.
• Competitive Landscape: Review strategic developments in the carrier screening market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.